Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, artherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2 m is 0, 1, 2, 4 or 5 q is 0 or 1 t is 0 or 1 R2 is alkyl from 1 to 3 carbon atoms R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms A is phenyl, unsubstituted or substituted by or 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy or cycloaldyl having from 3 to 6 ring carbon atoms wherein the cycloaldyl is unsubstitited or one or two ring carbons are independently mono-substituted by methyl or ethyl or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compounds of formula (I) by a ring carbon and R1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).La présente invention a trait à des agents de formule (I), utiles pour le traitement de divers troubles métaboliques, tels que le syndrome de résistance à linsuline, le diabète, lhyperlipémie, la stéatose hépatique, la cachexie, lobésité, lartériosclérose dans la formule (I) : n est 1 ou 2 m est 0, 1, 2, 4 ou 5 q est 0 or 1 R2 est alkyle comprenant 1 à 3 atomes de carbone R3 est hydrogène, halo, alkyle comprenant 1 à 3 atomes de carbone, ou alcoxy comprenant 1 à 3 atomes de carbone A est phényle, substitué ou non substitué par 1 ou 2 groupes choisis parmi : halo, alkyle ayant 1 ou 2 atomes de carbone, perfluorométhyle, alcoxy ayant 1 ou 2 atomes de carbone, et perfluorométhoxy ou cycloalkyle ayant 3 à 6 atomes de carbone cycliques dans lequel le cycloalkyle est non substitué ou un
